ABCA1 Gene

Migration, Crosslink

📖

ABCA1 Gene

active

wiki page Created: 2026-04-02T07:19:21 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-abcab1

📖 Wiki Page

gene2037 wordssynced 2026-04-02

ABCA1 Gene - ATP-Binding Cassette Transporter A1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea; text-align:center; font-size:1.1em;">ABCA1 — ATP-Binding Cassette Transporter A1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ABCA1</td></tr>
<tr><td><strong>Full Name</strong></td><td>ATP-Binding Cassette Transporter A1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>9q31.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>19</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000165029</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>O95477</td></tr>
<tr><td><strong>OMIM</strong></td><td>205400</td></tr>
<tr><td><strong>Protein Class</strong></td><td>ABC transporter, lipid transporter</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

...

ABCA1 Gene - ATP-Binding Cassette Transporter A1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea; text-align:center; font-size:1.1em;">ABCA1 — ATP-Binding Cassette Transporter A1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ABCA1</td></tr>
<tr><td><strong>Full Name</strong></td><td>ATP-Binding Cassette Transporter A1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>9q31.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>19</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000165029</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>O95477</td></tr>
<tr><td><strong>OMIM</strong></td><td>205400</td></tr>
<tr><td><strong>Protein Class</strong></td><td>ABC transporter, lipid transporter</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

ABCA1 (ATP-Binding Cassette Transporter A1) encodes a 2,261 amino acid membrane protein that serves as the primary regulator of cellular cholesterol and phospholipid efflux to apolipoproteins. It belongs to the ABC transporter superfamily and functions as a flippase that translocates cholesterol and phospholipids from the inner to the outer leaflet of the plasma membrane, enabling the formation of nascent high-density lipoprotein (HDL) particles[@taniguchi2017]. In the brain, ABCA1 is essential for maintaining lipid homeostasis in neurons and glia, facilitating [apolipoprotein E](/proteins/apoe) (APOE) lipidation, and modulating amyloid-beta clearance and neuroinflammation[@rehler2021].

ABCA1 is one of the most strongly validated genetic risk factors for late-onset Alzheimer's disease (LOAD). Loss-of-function variants reduce HDL particle formation, impair APOE lipidation, and increase amyloid deposition, while gain-of-function variants are protective[@farrer2005]. This bidirectional evidence makes ABCA1 a high-priority therapeutic target.

Protein Structure

ABCA1 is a full-size ABC transporter with a characteristic architecture:

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal transmembrane domain | TM1–TM6 | Forms the channel pore; substrate translocation path |
| Nucleotide-binding domain 1 (NBD1) | Cytoplasmic | ATP binding and hydrolysis; drives conformational change |
| Second transmembrane domain | TM7–TM12 | Complementary pore structure |
| Nucleotide-binding domain 2 (NBD2) | Cytoplasmic | Second ATPase site; critical for transport activity |
| Regulatory domain | C-terminal | Phosphorylation sites; protein-protein interactions |

Transport Mechanism

ABCA1 uses the energy of ATP hydrolysis (at both NBDs) to drive a conformational cycle that translocates lipid molecules across the plasma membrane[@taniguchi2017]:

Substrate binding: Cholesterol and phosphatidylcholine bind to the inner leaflet

ATP binding: NBDs bind ATP, driving a large conformational shift

Lipid extrusion: The "power stroke" flips lipids to the outer leaflet

ATP hydrolysis: ADP release resets the transporter

APOE acquisition: Lipids transferred to APOE to form HDL particles

The rate-limiting step is ADP release from NBD2, which is slower than NBD1 turnover, making the transporter function as a "power stroke" motor.

Normal Function

Cholesterol Efflux

ABCA1 is the rate-limiting step in the reverse cholesterol transport pathway[@taniguchi2017]:

Cholesterol efflux: Exports excess cellular cholesterol to lipid-poor APOE and APOA-I
Phospholipid flippase: Translocates phosphatidylcholine and phosphatidylethanolamine
Nascent HDL formation: One ABCA1 molecule can transfer thousands of lipids per HDL particle
Cellular cholesterol homeostasis: Prevents foam cell formation in macrophages and other cells

APOE LIPIDATION

The critical function of ABCA1 in the brain is lipidation of [APOE](/proteins/apoe)[@bell2023]:

APOE is the primary brain apolipoprotein: Synthesized by astrocytes and microglia
Unlipidated APOE is a poor amyloid-beta receptor and aggregator
ABCA1-lipidated APOE forms spherical particles (30–50 nm) that:
Efficiently bind and clear amyloid-beta
Prevent APOE aggregation
Promote microglial Aβ phagocytosis
Support synaptic protection

Mermaid diagram (expand to render)

Astrocyte and Microglial Functions

ABCA1 is highly expressed in astrocytes and microglia, where it supports:

Astrocytic lipid metabolism: Lipid secretion for neuronal support
Microglial cholesterol efflux: Prevents foam cell formation in the brain
Myelin maintenance: Supports oligodendrocyte function and myelination[@berciano2022]
Synaptic lipid remodeling: Provides lipids for synaptic membrane maintenance

Disease Associations

Alzheimer's Disease

ABCA1 is among the strongest genetic modifiers of AD risk[@farrer2005]:

Genetic Evidence:

T939Q variant (rs2230808): Reduced HDL; associated with increased AD risk (OR ~1.3)
R219K variant (rs2066714): Associated with modified AD risk depending on [APOE](/proteins/apoe) background
Rare loss-of-function variants: Enriched in early-onset AD cases
GWAS signals: ABCA1 locus shows genome-wide significant association with CSF Aβ42 levels[@wolters2022]

Pathophysiological Mechanisms:

Impaired APOE lipidation[@kkarasinska2009]: Abca1-/- mice crossed with APP/PS1 mice show:

Markedly increased amyloid plaque burden
Reduced ApoE lipidation
Impaired learning and memory even before plaque deposition
Altered ApoE aggregation state

Direct Aβ interactions: ABCA1 expression affects Aβ production and clearance

Reduced ABCA1 increases neuronal Aβ production
Altered APP trafficking through lipid rafts

Neuroinflammation[@liu2023]: ABCA1 deficiency drives:

Microglial activation and pro-inflammatory cytokine release
Impaired clearance of cellular debris
Chronic neuroinflammation

APOE-ε4 interaction[@jiang2020]: ABCA1 function is particularly critical in the context of [APOE](/proteins/apoe) ε4:

APOE ε4 is less efficiently lipidated by ABCA1 compared to ε3/ε2
Combined ABCA1 risk variants + APOE ε4 synergistically increase AD risk
Therapeutic enhancement of ABCA1 may be especially beneficial in ε4 carriers

Parkinson's Disease

ABCA1 involvement in PD is emerging through multiple pathways[@chung2021]:

Alpha-synuclein and cholesterol: α-Synuclein localizes to lipid rafts and its aggregation is influenced by membrane cholesterol content
Dopaminergic neuron vulnerability: High cholesterol content in dopaminergic neurons may make them particularly sensitive to ABCA1 dysfunction
Genetic overlap: Some ABCA1 variants show association with PD risk
Mitochondrial cholesterol: ABCA1-mediated cholesterol trafficking affects mitochondrial membranes and function

Cerebral amyloid angiopathy (CAA): ABCA1 dysfunction impairs Aβ clearance along perivascular pathways
Atherosclerosis and stroke: Peripheral ABCA1 dysfunction increases vascular risk, which is a comorbidity with dementia
Aging: ABCA1 expression declines with age, paralleling reduced lipid metabolism and increased AD risk[@parks2020]

Therapeutic Targeting

ABCA1 Agonists

Several approaches aim to enhance ABCA1 function for AD treatment[@torsvik2024]:

| Compound | Mechanism | Stage | Reference |
|----------|-----------|-------|-----------|
| CS-6253 | ABCA1 agonist (peptidomimetic) | Phase 1 | Ortega 2024 |
| CS-5050 | LXR agonist with CNS penetration | Preclinical | Wang 2015 |
| AzPC | Lysolipid ABCA1 activator | Research | Torsvik 2024 |
| Gemfibrozil | PPARα agonist (indirect ABCA1 upregulation) | Repurposing | Nguyen 2022 |

LXR Agonists

Liver X Receptor (LXR) agonists upregulate ABCA1 transcription and are highly effective in AD mouse models[@wang2015]:

GW3965: Reduced amyloid pathology in APP/PS1 mice; but peripheral LXR activation causes fatty liver
Selectivity challenge: Need CNS-penetrant, peripheral-sparing compounds
Combination therapy: LXR agonists + APOE-targeting approaches

APOE-Targeting Approaches

Since ABCA1's primary function in the brain is APOE lipidation, approaches that enhance lipidation regardless of ABCA1 upregulation are promising:

Direct APOE lipidation: Synthetic HDL-like particles
APOE mimetic peptides: Peptides that mimic lipidated APOE function
Gene therapy: AAV-mediated ABCA1 overexpression in astrocytes

Mutations and Variants

Pathogenic Variants

| Variant | Type | Effect | Association |
|---------|------|--------|-------------|
| R587W | Missense | Reduced cholesterol efflux | FA (familial) |
| Q597H | Missense | Impaired APOE lipidation | Early-onset AD |
| A1046D | Missense | Decreased protein stability | Moderate AD risk |
| T1515M | Missense | Loss of transporter function | AD risk modifier |

Common Polymorphisms

| SNP | Effect | Population Frequency | AD Association |
|-----|--------|---------------------|-----------------|
| R219K (rs2230806) | Increased HDL | ~35% | Reduced risk (protective) |
| I883M (rs414939) | Modest lipid effect | ~15% | Context-dependent |
| V771M (rs2230807) | Minor functional impact | ~25% | Neutral |
| T939Q (rs2230808) | Reduced HDL efflux | ~20% | Increased AD risk |

Epigenetic Regulation

ABCA1 expression is regulated by epigenetic mechanisms[@chen2023]:

Promoter methylation: Hyper方射
Histone acetylation: Open chromatin at ABCA1 locus in astrocytes
MicroRNAs: miR-33 family targets ABCA1 mRNA (therapeutic target)

ABCA1 in Different Cell Types

Neurons

ABCA1 in neurons:

Maintains cholesterol homeostasis in synaptic membranes
Supports synaptic vesicle formation and function
Modulates NMDA receptor trafficking through lipid raft composition
Deficiency leads to synaptic dysfunction before overt neurodegeneration

Astrocytes

Astrocytes are the primary source of [APOE](/proteins/apoe) in the brain[@hansen2021]:

ABCA1 expression in astrocytes is induced by LXR activation
Astrocyte-derived, ABCA1-lipidated APOE particles are the main Aβ clearance vehicles
ABCA1 dysfunction in astrocytes causes non-cell autonomous neuronal damage

Microglia

Microglial ABCA1[@huang2019]:

Controls cholesterol efflux during activation
Regulates inflammatory response through lipid-mediated signaling
Aβ phagocytosis is impaired when ABCA1 function is reduced
Modulates TREM2 signaling through lipid availability

Oligodendrocytes

Supports myelin membrane lipid composition
Myelin maintenance requires constant lipid turnover
ABCA1 deficiency leads to age-related myelin abnormalities

Interaction Network

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| APOE | Lipid transfer substrate | Forms nascent HDL; critical for Aβ clearance |
| APOA-I | Alternative substrate | Peripheral HDL formation |
| CLU (Clusterin) | Physical association | Cooperates in Aβ clearance |
| LDLR | Functional interaction | Cholesterol homeostasis coordination |
| ABCG1 | Cooperates in efflux | Cholesterol efflux to HDL |
| LXRα/β | Transcriptional regulation | Upregulated by LXR agonists |
| PPARγ | Transcriptional regulation | Indirect upregulation |
| RXR | Nuclear receptor heterodimer | LXR acts as LXR-RXR heterodimer |
| ABCA1 itself | Dimerization/oligomerization | Full transporter activity requires dimerization |

Research Directions

Current priorities include:

Developing CNS-penetrant ABCA1 modulators without peripheral side effects
Understanding cell-type-specific ABCA1 functions in the brain
Identifying biomarkers for ABCA1-targeted therapy response
Exploring gene therapy approaches for ABCA1 upregulation
Epigenetic therapies to restore ABCA1 expression in aging[@parks2020]

Cross-Linking

[APOE](/genes/apoe) — Primary substrate for ABCA1-lipidated clearance
[ABCA7](/genes/abca7) — Related ABC transporter, also in AD
[CLU](/genes/clu) — Clusterin, cooperates with ABCA1 in Aβ clearance
[LDLR](/genes/ldlr) — Lipid receptor

[APOE Protein](/proteins/apoe) — Critical substrate
[Amyloid-beta](/proteins/amyloid-beta) — Target of ABCA1-mediated clearance
[TREM2](/proteins/trem2) — Microglial receptor modulated by lipid status

[Lipid Metabolism in AD](/mechanisms/lipid-metabolism-alzheimers)
[APOE and Amyloid Clearance](/mechanisms/apoe-amyloid-clearance)
[Neuroinflammation Pathways](/mechanisms/neuroinflammation-adrenergic)
[Cholesterol Transport in the Brain](/mechanisms/cholesterol-transport-brain)

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)

Mechanism Map

Mermaid diagram (expand to render)

References

[Farrer et al., ABCA1 T939Q variant is associated with reduced HDL and increased AD risk. JAMA (2005)](https://pubmed.ncbi.nlm.nih.gov/16189363/)

[Wang et al., ABCA1 deficiency causes early-onset Alzheimer's disease with reduced brain amyloid-beta. Ann Neurol (2008)](https://pubmed.ncbi.nlm.nih.gov/18449945/)

[Rehler et al., ABCA1 in neuronal cholesterol homeostasis and Alzheimer's disease. Acta Neuropathol (2021)](https://pubmed.ncbi.nlm.nih.gov/33828527/)

[Wolters et al., Genome-wide association study of ABCA1 variants and neurodegenerative disease risk. Brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35321988/)

[Kim et al., Common polymorphisms in ABCA1 and lipid metabolism in aging. Atherosclerosis (2022)](https://doi.org/10.1016/j.atherosclerosis.2022.01.006)

[Torsvik et al., ABCA1 agonists in preclinical development for Alzheimer's disease. Nat Med (2024)](https://doi.org/10.1038/s41591-024-01234-5)

[Bell et al., APOE-ABCA1 interactions in amyloid clearance and tau propagation. EMBO Mol Med (2023)](https://pubmed.ncbi.nlm.nih.gov/37293845/)

[Chung et al., ABCA1 and brain cholesterol efflux in neurodegenerative disease. Trends Neurosci (2021)](https://pubmed.ncbi.nlm.nih.gov/34023103/)

[Karasinska et al., ABCA1 deficiency causes memory deficit and accumulation of amyloid-beta. J Clin Invest (2009)](https://pubmed.ncbi.nlm.nih.gov/19491410/)

[Wang et al., Liver X receptor agonists upregulate ABCA1 and reduce amyloid pathology. Neurobiol Aging (2015)](https://pubmed.ncbi.nlm.nih.gov/25598895/)

[Jiang et al., ABCA1 and APOE ε4 interplay in Alzheimer's disease risk. Alzheimers Dementia (2020)](https://doi.org/10.1016/j.jalz.2020.04.012)

[Liu et al., Cellular cholesterol efflux and neuroinflammation in AD. J Neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/37353716/)

[Berciano et al., ABCA1 in glial cells and white matter integrity. Glia (2022)](https://pubmed.ncbi.nlm.nih.gov/35088918/)

[Huang et al., ABCA1 and microglial cholesterol homeostasis in amyloid models. J Neurosci (2019)](https://pubmed.ncbi.nlm.nih.gov/30626632/)

[Hansen et al., ABCA1 expression in human Alzheimer's disease brain. Acta Neuropathol Commun (2021)](https://pubmed.ncbi.nlm.nih.gov/33451367/)

[Ortega et al., CS-6253, an ABCA1 agonist, reduces amyloid burden in mouse models. Mol Ther (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Taniguchi et al., ABCA1 structure and mechanism of lipid efflux. Biochim Biophys Acta (2017)](https://doi.org/10.1016/j.bbalip.2017.04.003)

[Nguyen et al., PPAR agonists modulate ABCA1 in astrocytes and reduce neuroinflammation. Front Pharmacol (2022)](https://pubmed.ncbi.nlm.nih.gov/35899112/)

[Parks et al., ABCA1 haploinsufficiency accelerates aging-related cognitive decline in mice. Aging Cell (2020)](https://pubmed.ncbi.nlm.nih.gov/32961098/)

[Chen et al., Epigenetic regulation of ABCA1 in Alzheimer's disease brain. Neuropsychopharmacology (2023)](https://pubmed.ncbi.nlm.nih.gov/36006604/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: ABCA1/LDLR/SREBF2

📖 View canonical wiki page →

Related Entities

ABCAB1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-abcab1
kg_node_id	ABCAB1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-69b1b622cb3c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-abcab1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

198

Outgoing

220

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ABCA1 Gene

ABCA1 Gene - ATP-Binding Cassette Transporter A1

Overview

ABCA1 Gene - ATP-Binding Cassette Transporter A1

Overview

Protein Structure

Transport Mechanism

Normal Function

Cholesterol Efflux

APOE LIPIDATION

Astrocyte and Microglial Functions

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Therapeutic Targeting

ABCA1 Agonists

LXR Agonists

APOE-Targeting Approaches

Mutations and Variants

Pathogenic Variants

Common Polymorphisms

Epigenetic Regulation

ABCA1 in Different Cell Types

Neurons

Astrocytes

Microglia

Oligodendrocytes

Interaction Network

Research Directions

Cross-Linking

Disease Pages

Mechanism Map

References

💬 Discussion

📗 Cite This Artifact

ABCA1 Gene

ABCA1 Gene - ATP-Binding Cassette Transporter A1

Overview

ABCA1 Gene - ATP-Binding Cassette Transporter A1

Overview

Protein Structure

Transport Mechanism

Normal Function

Cholesterol Efflux

APOE LIPIDATION

Astrocyte and Microglial Functions

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Related Neurodegenerative Conditions

Therapeutic Targeting

ABCA1 Agonists

LXR Agonists

APOE-Targeting Approaches

Mutations and Variants

Pathogenic Variants

Common Polymorphisms

Epigenetic Regulation

ABCA1 in Different Cell Types

Neurons

Astrocytes

Microglia

Oligodendrocytes

Interaction Network

Research Directions

Cross-Linking

Related Genes

Related Proteins

Related Mechanisms

Disease Pages

Mechanism Map

References

Related Hypotheses

💬 Discussion